Grant Proposal Guidelines
REQUEST FOR APPLICATION (RFA) for MARCH 1, 2015
Enabling Drug Screening for Ataxia Telangiectasia
The aim of this Request for Applications (RFA) is to encourage the discovery of cellular phenotypes and target proteins that are clinically relevant to Ataxia Telangiectasia (A-T) and then to develop assays that can be used to screen for compounds that modulate those phenotypes and targets. Funding will be awarded to individual researchers or research teams whose projects are deemed most likely to ultimately identify compounds that slow the neurodegeneration experienced by patients with A-T. Investigators may apply for either phase one or two of this RFA, or for both phases.
PHASE ONE: Identification of Cellular Phenotypes and Target Proteins
Up to US$75,000 for one year
Funding will be provided to employ innovative approaches in identifying robust, reproducible phenotypes or promising disease targets in neurons or neural stem cells differentiated from human A-T induced pluripotent stem cells. The research plan proposed by recipients of this award must reflect an understanding of the assays and targets required for medium- and high-throughput drug screening by world-class screening facilities. The A-T Children’s Project may request a planning meeting or teleconference for the grant recipient to confer with advisors in academia and/or industry to ensure the feasibility of phenotypes and targets for assay development.
PHASE TWO: Assay Development for Screening
Up to US$50,000 for one year
Investigators who have identified a clinically relevant cellular phenotype or chemically-tractable drug target for A-T may apply for phase two to support their development of a drug screening assay. Because assay development for compound screening involves many technical considerations, including miniaturization and scalability, the A-T Children’s Project may introduce the grant recipient to advisers experienced in these technical facets with whom they can work to develop the assay.
Please note that the A-T Children’s Project’s mission is to advance promising therapeutic compounds toward the clinic as rapidly as possible. Achieving this mission will likely involve supporting multiple investigators during phase two. The A-T Children’s Project must therefore be free to share any assay developed using this funding with other non-profit or for-profit organizations without restrictions imposed by, or compensation paid to, the investigators or institutions that developed the assay. In addition, the A-T Children’s Project’s expects investigators to willingly advise and collaborate with the other parties who utilize their assay for screening purposes.
The application deadline for this RFA is March 1, 2015. Decisions are typically communicated to applicants within 90 days.
Download RFA Application Form
We welcome investigators to contact Cynthia Rothblum-Oviatt, PhD, our Science Coordinator, if help is needed forming collaborations and/or obtaining reagents for A-T/ATM research.
Cynthia Rothblum-Oviatt, PhD
The A-T Children's Project strives to assist respected scientists around the world in developing a clearer understanding of ataxia-telangiectasia. We are determined to find a timely cure, or life-improving treatments, for this serious disease. Grant awards are made through a careful and detailed selection process. The members of our Scientific Advisory Board examine each proposal and make their independent recommendations to our Board of Directors which then votes on each proposed project. Proposals from junior investigators, from scientists in related disciplines, and from individuals with innovative new ideas for A-T research are particularly encouraged, as are laboratories and teams working together from industry as well as teaching universities.
The A-T Children's Project provides competitive grant awards for basic and translational research grants related to A-T. One- and two-year projects are funded up to a maximum total direct cost of US$75,000 per year.
National as well as international scientists are welcome to apply for funding.
Applicants please note that unless specific Requests for Applications are present, the A-T Children's Project is currently focusing its funding efforts on proposals that apply innovative and novel strategies for suggesting, developing and evaluating specific disease-modifying and symptomatic interventions with an emphasis on:
- translational (bench to bedside) research
- clinical studies
As such, these types of applications will be given priority funding.
Applicants should also be aware that meritorious proposals may be rejected if:
- The proposed research is too far from being relevant to a therapeutic intervention
- Our Scientific Advisory Board finds the research redundant and in no need of validation
- The proposed research is likely to happen anyway, without our support
- The research cannot realistically be achieved with the proposed budget
Letters of Intent
A Letter of Intent is not required. However, prior to submission of a full-length proposal, applicants seeking Scientific Advisory Board input may submit a Letter of Intent directly to the A-TCP Science Coordinator at
. This letter (not to exceed two pages) should include a brief abstract describing the proposed research, specific aims and an estimated budget with time frame.
Proposal Submission Information and Deadlines
Applicants must submit an electronic copy of their Proposal in either MSWord or PDF formats to
Submission deadlines for grant applications are September 1 and March 1 of each year (or the following business day if the deadline falls on a weekend or holiday).
Grants are reviewed and awarded quickly compared to most other grant-giving organizations. In most cases, a grant decision will be made and communicated to the applicant within 90 days after the grant application deadline.
Grant Proposal Application Form (MSWord)
A. The BODY OF THE PROPOSAL should be limited to ten pages (not including references, attached articles and CVs), but should have the quality of an NIH proposal.
B. In recognition of the growing need for increased reproducibility in all areas of research, basic, preclinical and clinical, the A-T Children’s Project recommends that investigators consider the points delineated by the NIH National Institute of Neurological Disorders and Stroke (NINDS) in their guidance document Improving the Quality of NINDS-Supported Preclinical and Clinical Research through Rigorous Study Design and Transparent Reporting. These points are presented in brief here:
- Rationale for the selected models and endpoints (animal and/or cellular)
- Adequacy of the controls
- Justification of sample size, including power calculation
- Statistical methods used in analysis and interpretation of results
- Methods of blinding (allocation concealment and blinded assessment of outcome)
- Strategies for randomization and/or stratification
- Reporting of data missing due to attrition or exclusion
- Reporting of all results (negative and positive)
- Independent validation/replication, if available
- Robustness and reproducibility of the observed results
- Dose-response results
- Verification that interventional drug or biologic reached and engaged the target
Interpretation of results:
- Alternative interpretations of the experimental data
- Relevant literature in support or in disagreement with the results
- Discussion of effect size in relation to potential clinical impact
- Potential conflicts of interest
C. Budgets for up to US$150,000 for a two-year project are acceptable. We do not pay for administrative overhead and indirect costs. We do not pay for institutional construction or renovation; purchase of major capital equipment other than directly needed for proposed experiments; office equipment or furniture; travel (except as required to perform the project); tuition fees; journal subscriptions; dues or memberships; printing or publishing costs.
D.All applicants funded will be required to provide six-month progress reports, as well as annual and final progress reports. These reports must be accompanied by signed financial statements (forms will be provided.)
E. Grant Proposals Requiring Institutional Review Board (IRB) Approval: Funding for such proposals will be dependent upon and commence after IRB approval of the study protocol.
Grant Proposal Application Form (MSWord)